EUCTR2015-005607-92-HU
Active, not recruiting
Phase 1
A Phase II randomized, placebo controlled, double-blind, multi-centre study to assess safety and efficacy of incremental doses of QGC001 in patients upon discharge or following hospitalization for worsening chronic heart failure with left ventricular systolic dysfunction Short title: QUantum genomics Incremental Dosing in Heart FailureAcronym QUID-HF” - QUantum genomics Incremental Dosing in Heart Failure - QUID-HF
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Patient with worsening chronic heart failure with left ventricular systolic dysfunction
- Sponsor
- Quantum Genomics
- Enrollment
- 75
- Status
- Active, not recruiting
- Last Updated
- 8 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\*A signed and dated informed consent form prior to any study procedure
- •\*Adult male subjects and female subjects without childbearing potential.
- •\*Clinical diagnosis of CHF with history of NYHA class II\-III for at least 3 months before randomisation.
- •\* Clinical diagnosis of WHF, as defined by a history of hospitalization for worsening symptoms of HF within the previous year. HF hospitalization is defined as an overnight stay in a hospital. Eligible subjects may be enrolled at any time before discharge from an episode of decompensated HF or during a post\-discharge ambulatory state within one year of admission for WHF, if they fulfil all inclusion/exclusion criteria.
- •\*Documented left ventricular ejection fraction (LVEF) ? 40% measured by any modality within the previous 12 months in the subject’s medical history.
- •\*Subjects must also have at least one local measurement of BNP level \= 300 pg/mL or NT\-proBNP level \=1200 pg/mL (preferred assay, local laboratory) at the screening visit (maximum 7 days before randomisation).
- •\*eGFR \> 45 mL/min/1\.73 m2 (MDRD) at screening.
- •\*Serum potassium ? 5\.0 mmol/L at screening.
- •\*Systolic blood pressure ?110 mmHg (average of 3 consecutive measurements) at screening.
- •\*Prescribed to optimal pharmacologic therapy per ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012”, or based on the updated current clinical practice, unless contra\-indicated or not\-tolerated, and on a stable dose for at least 30 days prior to enrolment (the dosage of the drugs cannot be increased or decreased respectively by more than double or half of initial dosage).
Exclusion Criteria
- •\*BMI \> 35 kg.m\-2 .
- •\*Patients who require the use of HF IV therapy or oral furosemide \> 250 mg (or equivalent) at any time during the 48 hours immediately before randomisation.
- •\*Patients with unstable angina, myocardial infarction, PTCA, coronary artery bypass graft, cerebral vascular accident, or transient ischemic attack within previous 3 months (90 days) before enrolment.
- •\*Patients whose primary cause of heart failure is mitral or aortic valve disease or congenital heart disease or hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g. amyloidosis, sarcoidosis) or myocarditis.
- •\* Patients with new” permanent atrial fibrillation (AF), discovered within 3 months prior to randomization.
- •\* Heart rate \> 90 beats/min at screening.
- •\*Patients scheduled for Pacemaker (including ICD, CRT), Angioplasty, CABG or LVAD within the next 3 months.
- •\*Patients with documented chronic obstructive lung disease, defined as chronic need for oxygen therapy and/or daily\-inhaled corticosteroid and/or daily bronchodilator treatment.
- •\*eGFR \< 45 mL/min/1\.73 m2 (MDRD) at screening.
- •\* Decrease in eGFR greater than 20% within 3 weeks prior to the screening visit..
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
An European study to assess safety and efficacy of a new drug in patients with worsening chronic heart failurePatient with worsening chronic heart failure with left ventricular systolic dysfunctionMedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2015-005607-92-PLQUANTUM GENOMICS75
Active, not recruiting
Phase 1
An European study to assass safety and efficacy of a new drug in patients with worsening chronic heart failure.Patient with worsening chronic heart failure with left ventricular systolic dysfunctionMedDRA version: 20.0Level: LLTClassification code 10019279Term: Heart failureSystem Organ Class: 100000011680Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2015-005607-92-CZQuantum Genomics75
Active, not recruiting
Phase 1
A Phase II Study in Patients With Moderate to Severe Active Crohn’s Disease.Crohn’s DiseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersTherapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2018-003303-19-PLReistone Biopharma Company Limited144
Completed
Phase 2
A Phase II randomized, placebo controlled, double-blind, multi-centre study to assess safety and efficacy of incremental doses of QGC001 in patients with NYHA class II/III chronic heart failure with left ventricular systolic dysfunctioNL-OMON46235European Drug Development Hub, Fondation Force13
Active, not recruiting
Phase 1
A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis.lcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856Therapeutic area: Diseases [C] - Digestive System Diseases [C06]EUCTR2018-003364-31-PLReistone Biopharma Company Limited152